Actively Recruiting
Vinpocetine in Patients With Parkinsonian Disease
Led by Tanta University · Updated on 2025-12-10
60
Participants Needed
1
Research Sites
105 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The clinical manifestations of Parkinson's disease (PD), a chronic neurodegenerative condition, include resting tremor, hypokinesia, bradykinesia, stiffness and postural instability. These motor symptoms are caused by a selective loss and degeneration of dopaminergic neurons in the substantia nigra pars compacta (SNpc) region, which leads to a dopamine (DA) insufficiency in the striatum
CONDITIONS
Official Title
Vinpocetine in Patients With Parkinsonian Disease
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 50 to 70 years
- Both male and female participants are eligible
- Negative pregnancy test and use of effective contraception for females
- Diagnosed with Parkinson's disease
- Currently taking levodopa medication for Parkinson's disease
You will not qualify if you...
- Parkinsonism caused by other secondary conditions
- Taking anti-inflammatory drugs
- Having atypical parkinsonian syndromes
- Previous stereotaxic surgery for Parkinson's disease
- Pregnant or breastfeeding women
- Having cardiovascular disease
- Having blood clotting disorders
- Having active cancer
- Addiction to alcohol or drugs
- Known allergy to the study medications
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Tanta Unuversity
Tanta, Egypt, 31527
Actively Recruiting
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here